Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Mr. Klausner has been a consultant to the biopharmaceutical industry since 2009 and currently serves as Executive Chairman of Concarlo Therapeutics, Inc. From 2018 to 2022, he served as President, Chief Executive Officer, and a Director of the start-up drug development company Goldilocks Therapeutics, Inc. He served as CEO of Gem Pharmaceuticals, LLC (“Gem”) from 2012 until Gem’s drug development assets were acquired by Monopar in 2017. In addition, he was CEO of Jade Therapeutics Inc. from 2012 to 2015. Previously, Mr. Klausner spent a total of 18 years at the life science venture capital firms Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.

Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Mr. Klausner has been a consultant to the biopharmaceutical industry since 2009 and currently serves as Executive Chairman of Concarlo Therapeutics, Inc. From 2018 to 2022, he served as President, Chief Executive Officer, and a Director of the start-up drug development company Goldilocks Therapeutics, Inc. He served as CEO of Gem Pharmaceuticals, LLC (“Gem”) from 2012 until Gem’s drug development assets were acquired by Monopar in 2017. In addition, he was CEO of Jade Therapeutics Inc. from 2012 to 2015. Previously, Mr. Klausner spent a total of 18 years at the life science venture capital firms Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.

Mr. Klausner has been a consultant to the biopharmaceutical industry since 2009 and currently serves as Executive Chairman of Concarlo Therapeutics, Inc. From 2018 to 2022, he served as President, Chief Executive Officer, and a Director of the start-up drug development company Goldilocks Therapeutics, Inc. He served as CEO of Gem Pharmaceuticals, LLC (“Gem”) from 2012 until Gem’s drug development assets were acquired by Monopar in 2017. In addition, he was CEO of Jade Therapeutics Inc. from 2012 to 2015. Previously, Mr. Klausner spent a total of 18 years at the life science venture capital firms Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.

Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.